IMQT_020

IMQT_020 is a selective allosteric SLC1A5_var inhibitor. iMQT_020 disrupts the trimeric assembly of SLC1A5_var, causing metabolic crisis in cancer cells and selectively suppressing their growth. iMQT_020 reduces glutamine anaplerosis and oxidative phosphorylation, resulting in a broad disruption of cancer metabolism. iMQT_020 reduces GSH levels and increases cellular ROS and mitochondrial ROS. iMQT_020 induces apoptosis and ferroptosis. iMQT_020 can epigenetically upregulate PD-L1 expression. iMQT_020 can be used for the study of pancreatic cancer, lung cancer, and colon cancer[1].

Product Specifications

CAS Number

[2463893-46-9]

UNSPSC

12352005

Target

Apoptosis; Ferroptosis; Glutathione Peroxidase; PD-1/PD-L1; Reactive Oxygen Species (ROS)

Related Pathways

Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Field of Research

Cancer

Smiles

ClC1=C(O)C=C(F)C(C2=CC=C(NC(NC3=O)=O)C3=C2)=C1

Molecular Formula

C14H8ClFN2O3

Molecular Weight

306.68

References & Citations

[1]Sung Y, et al. Targeting cancer glutamine dependency with a first-in-class inhibitor of the mitochondrial glutamine transporter SLC1A5_var. Nat Commun. 2025 Nov 3;16 (1) :9690.